Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr. Chew is the expert leader in AMD. She has her own wiki page. Lol
https://en.m.wikipedia.org/wiki/Emily_Chew
This is going to get good.
Guys, the name Metformin alone is exciting. Metformin is a buzz word in the pharmaceutical world. It’s anti diabetic properties is it’s commercial use but it has anti aging popularity. It was even featured on a Joe Rogan podcast.
Metformin called a wonder drug and now it’s going to be an eye drop.
What I’m saying is I’m hoping we see some magic here with CUBT in 2022.
Dr. Chew is the CHIEF of Clinical Trials. She’s in a position of influence for investigation review boards and is going to vote Yes to advance to trials once she backs the study protocol or protocols (might be various trials at the same time).
What I’m saying is she is a Titan!
No need to have a research center or lab when you can use the US Governments now. Nice move here.
FDA may look favorable towards approving an IND since they have significant relationships with NIH/NEI. That’s priceless!
Patience and optimism moving forward!
CRADA just ensured legitimacy!
CUBT just partnered with the US Government.
Expecting a filing of CRADA to SEC.
Brilliant leverage and will become very attractive to Big Pharma. This just made CUBT a real developer.
No evidence on Hans. pdgood just likes telling stories about.
Not one time ever has pdgood posted anything regarding Hans or MEDH legal allegations.
The only scam here is pdgood posting Fear.
You may need to complete your character bible and finish your true crime book.
Nothing to do with MEDH.
2022! A heart beat detected.
6 month grace period on principal. Let’s get a deal done within 6 months.
Looks like a standard bridge loan from a company with licensed assets and no revenue. Terms expected.
Start up financing for a start up company
Dallas Seller Club
The people have spoken with Zero to low trade volume.
Your turn Hans. File the financials so we can forgive and forget and you can move forward with building this company.
Fantastic entry price for newcomers.
The word by NP through LinkedIn message is Denver opens April.
Q1 quiet period turbulence ongoing.
March 31 Revenue reports on 2021 must be > $100,000
So your agenda is no agenda?
So what outcome you wanting to see here at MEDH?
Hans bro. Stick to Hans.
Post links regarding Hans.
Regardless of the last name what’s your point? How is this relevant today? We all know litigation is happening.
What’s relevant today with MEDH/Hans? That’s what matters.
Evidence not words.
The problem is that it’s old and sec already initiated litigation. This all happened last summer … actually open this link and see the date. Come on bro, do better, be better.
https://www.sec.gov/litigation/complaints/2021/comp25253.pdf
I agree. Current before EXPO would be wise.
Not true. It’s Mark Miller
https://www.sec.gov/litigation/complaints/2021/comp25253.pdf
Unless you care to show the link.
Pfizer ???
You meant to dictate Moderna.
Isn’t that how money is made in the OTC. At this level nothing is weird. It’s all speculation. If you are right and have loaded at these levels you win big. If you are wrong well… you end up in OTC purgatory for a few years. Lol
Hans needs to get current. If he posted on Twitter that filings soon. And the Transfer Agent pending. Then he would be liable for mis leasing statement of that magnitude. I don’t think you can loosely make statements of that importance. We will see what happens.
MEDH acquired Lazydaze.
https://finance.yahoo.com/news/medx-holdings-inc-continues-grow-190000795.html
Just need Hans to decide he is ready to run a PubCo.
https://www.delta9expo.com/
Hans present at 4:15pm time slot
10k right?
Best of luck to you. Everyone starts somewhere. But keep growing.
CUBT will see tremendous success imo.
2022! See y’all at $0.20 soon… gonna crawl up daily.
Ocular studies going on. Toxicology studies will be next… then IND for metformin.
Robot in at 0.02’s … he’s fine. Just being his normal self.
Did you just post about Canadian Cannabis on CUBT Biotech board?
Stay focused!
Q3/Q4 financials soon.
Let’s see what these businesses do!
CUBT 2022!
So question is… How’s my dictate?
I like this board more when SP is going up!
Exactly Ox
That’s why shares added prior to a material event have a bigger risk but… bigger reward.
Those with time invested in DD here know it’s coming… IND filing and clinical trial!
When?… when the time is right.
Same as someone buying at 0.07 with 4 licenses versus someone buying at .70 after first IND filing.
We take a bigger risk at 0.07 without zero development.
The problem is you keep looking at this a a Share Price.
If you start looking at this as a company who over 2 years has assembled a strong experience team and has 4 licensed drug programs you will stop having panic attacks everyday.
Progress is visible from a company aspect. Simply re read all the previous PRs and put them on a timeline… progress. Only regrets here when the first IND is filed whether this year or next is that more shares were not added at 0.07.
Ed move from business class to first class with another 10k! Lol
Good job bro. Best of luck to you!
Add/Hold!
2022 is going to be fun!
Those who bought a .007 took a bigger risk than those at 0.02 so they reap bigger rewards.
OTC rewards risk and patience.
https://equiniti.com/us/news-and-views/eq-views/what-is-a-transfer-agent/
Hans on Twitter says “ Been waiting for our TA Equiniti to provide OTC with some requested docs. OTC fees are paid, we're just waiting. This takes way longer than it should”
My guess is OTCMarkets wants something validated and cleaned up before VERD* is authorized?
Austero/StockTwits: Listen to the CEO interview in its entirety. At time 07:30 he gets into the model of the company. Curative model ain’t to take drugs to the market it’s to acquire assets, develop to next stage , and sell or partner the assets. So the image that was shared is the target along the pathway where they hope to make an inflection (bring significant attention and make money).
Go to time 7:30 Eagle and listen to Richard Garr!
https://static1.squarespace.com/static/56e9d2c427d4bdf375c7e7aa/t/616e2679506995223fd1373b/1634608797671/CUBT+CEO+Richard+garr+Gives+Us+Updates+On+The+Pipeline%2C+COVID+Vaccine%2C+and+Dr+-+1080WebShareName.m4a/original/CUBT+CEO+Richard+garr+Gives+Us+Updates+On+The+Pipeline%2C+COVID+Vaccine%2C+and+Dr+-+1080WebShareName.m4a
CUBT is only interested in filing IND or phase 1 small clinical trial… then partner or sell the asset.
CUBT isn’t a pharmaceutical company… they are Lease, Value-Add, and Partner or Sell asset company.
Lol. A 2 year quiet period!
The company needs to PR their updated presentation!
Would be great for CEO to blog a summary of key points.
Take a look at it in depth. The gold nuggets are found there. Nice catalyst coming our way. I can’t believe they would put MODERNA* on blast there!
Several statements about preparing and readiness for various clinical trials